【學術演講】Trimannosyl antibody: Glycoengineering Based Antibody Drug Conjugate Platform

2021 神醫中心學術演講 (現場+視訊) 

日期 : 9月 28日星期二

時間 : 上午11:00  

地點 國衛院竹南院區/ 行政大樓B1第1會議室 

主題 : Trimannosyl antibody: Glycoengineering Based Antibody Drug Conjugate Platform

講師 : 蔡士昌所長( Shih-Chong Tsai, Ph.D)

財團法人生物技術開發中心 生物製藥研究所


視訊系統 Webex  : 會議連結

摘要

We report a high efficiency glycogengineering technology by using a GnT-I and a GnT-II (GnT :UDP N-Acetyl glucosamine transferase) to conjugate a novel tri-mannosyl antibody. Our results show that a tri-mannosyl Trastuzumab 2(GlcNAc-triazole-DBCO-(PEG)4-DM1)-2(GlcNAc-triazole- DBCO-PEG4-Vc- PAB- (PEG)2-Duocarmycin SA) is generated with the conversion efficiency over 95% and 80% recovery rate. The biological activities of ADC products produced were further confirmed by the similar Her2 ECD binding KD to that of l Kadcyla and cytotoxic activities to a Kadcyla-resistant cell line MDA-MB-175VI I. These studies suggest that GnT-1 and GnT-2 have very good potentials to develop a site-specific dual payload ADC platform when a tri-mannosyl antibody is used as start material.

2021-9-20

 61 total views,  1 views today

Comments are closed.